[Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed?]
- PMID: 17086144
- DOI: 10.1016/s0035-3787(06)75120-7
[Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed?]
Abstract
Introduction: Gaucher's disease (GD), the most prevalent inherited lysosomal storage disorder, is caused by deficient glucocerebrosidase activity. The resulting accumulation of glucocerebrosides in lysosomes of macrophages leads to hepatosplenomegaly, anemia, thrombocytopenia, and various bone manifestations. Gaucher's disease is classified into 3 types based on the nature of its effects on the central nervous system. Type 1, the most common variant, is classically nonneuronopathic. However, the occurrence of Parkinsonism seems to be more frequent in type I Gaucher's disease than in the general population. Furthermore, heterozygotes for certain glucocerebrosidase gene mutations have a higher risk to develop Parkinson's disease.
Observations: We report our experience about 9 patients with Gaucher's disease and their association with neurological manifestations.
Conclusion: These recent data may discuss Gaucher's classification and the existence of a continuum between neurologic and non-neurologic forms of the disease.
Similar articles
-
Gaucher's disease in pregnancy.Obstet Gynecol Surv. 1996 Sep;51(9):549-58. doi: 10.1097/00006254-199609000-00022. Obstet Gynecol Surv. 1996. PMID: 8873155 Review.
-
Imiglucerase and its use for the treatment of Gaucher's disease.Expert Opin Pharmacother. 2008 Aug;9(11):1987-2000. doi: 10.1517/14656566.9.11.1987. Expert Opin Pharmacother. 2008. PMID: 18627336 Review.
-
Enzymic differentiation of neurologic and nonneurologic forms of Gaucher's disease.J Neuropathol Exp Neurol. 1982 Nov;41(6):630-41. doi: 10.1097/00005072-198211000-00006. J Neuropathol Exp Neurol. 1982. PMID: 6813430
-
Gaucher's disease in Lithuania: its diagnosis and treatment.Medicina (Kaunas). 2011;47(7):405-11. Medicina (Kaunas). 2011. PMID: 22112991
-
[Gaucher's disease - an overview about a sphingolipidosis].Ther Umsch. 2018 Nov;75(4):209-214. doi: 10.1024/0040-5930/a000992. Ther Umsch. 2018. PMID: 30468119 German.
Cited by
-
Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III.Neuroradiology. 2009 Nov;51(11):773-9. doi: 10.1007/s00234-009-0548-1. Epub 2009 Jul 15. Neuroradiology. 2009. PMID: 19603156
-
Enzyme replacement and substrate reduction therapy for Gaucher disease.Cochrane Database Syst Rev. 2015 Mar 27;2015(3):CD010324. doi: 10.1002/14651858.CD010324.pub2. Cochrane Database Syst Rev. 2015. PMID: 25812601 Free PMC article.
-
Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.Mov Disord. 2010 Jul 30;25(10):1364-72. doi: 10.1002/mds.23046. Mov Disord. 2010. PMID: 20629126 Free PMC article.
-
Adult Gaucher disease in southern Tunisia: report of three cases.Diagn Pathol. 2012 Jan 10;7:4. doi: 10.1186/1746-1596-7-4. Diagn Pathol. 2012. PMID: 22233685 Free PMC article.
-
The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).J Inherit Metab Dis. 2010 Aug;33(4):331-8. doi: 10.1007/s10545-010-9095-5. Epub 2010 Jun 2. J Inherit Metab Dis. 2010. PMID: 20532983
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical